IPP Bureau
Syngene reports 18% jump in Q3 FY25 PAT at Rs. 131 Cr
By IPP Bureau - January 24, 2025
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
Neuland Labs board approves Capex of Rs. 342 Cr
By IPP Bureau - January 23, 2025
The company plans to fund this Capex through debt and internal accruals and expects the project to be completed by FY27
Piramal Critical Care announces US launch of Chlorpromazine Hydrochloride for Injection
By IPP Bureau - January 23, 2025
The launch of Chlorpromazine Hydrochloride for Injection is the latest in a series of recent product launches from Piramal Critical Care
Zydus announces USFDA Orphan Drug Designation to Usnoflast for treatment of ALS
By IPP Bureau - January 23, 2025
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
Strides Pharma debuts with ESG rating of 76/100 in the S&P Global’s CSA 2024
By IPP Bureau - January 23, 2025
Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance
Dr Reddy’s Labs Q3 FY25 profit up 2% YoY at Rs. 1,413 Cr
By IPP Bureau - January 23, 2025
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
Budget 2025: Industry expects tax incentives and thrust on affordable healthcare
By IPP Bureau - January 23, 2025
Expand the scope of the Production-Linked Incentive (PLI) scheme and increase its allocation to cover more pharmaceutical products and raw materials
Glenmark Pharmaceuticals USA launches Phytonadione Injectable Emulsion USP
By IPP Bureau - January 22, 2025
According to IQVIATM sales data for the 12-month period ending November 2024, the Vitamin K1 Injectable Emulsion USP, 10 mg/mL market achieved annual sales of approximately $19.7 million
Kwality Pharmaceuticals receives SFDA GMP approval for 2 units
By IPP Bureau - January 22, 2025
This certification will open new markets for the Kwality Pharma
Catalent to further expand Galapagos’ decentralized CAR-T manufacturing network in US
By IPP Bureau - January 22, 2025
New Jersey-based manufacturing site to support innovative decentralized approach for improved patient experience
Sunshine Biopharma launches Olanzapine and Olanzapine ODT
By IPP Bureau - January 22, 2025
Olanzapine is indicated for the acute and maintenance treatment of schizophrenia and related psychotic disorders
Strides receives USFDA approval for Acetaminophen and Ibuprofen Tablets
By IPP Bureau - January 21, 2025
The Acetaminophen and Ibuprofen tablets will be manufactured at the company’s flagship facility in KRSG, Bengaluru
European Commission expands Jemperli plus chemotherapy approval for endometrial cancer
By IPP Bureau - January 21, 2025
Jemperli plus chemotherapy is the only immuno-oncology-based treatment to show statistically significant and clinically meaningful OS benefit in the overall population
Moderna announces updates on pandemic influenza program
By IPP Bureau - January 21, 2025
The project will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines
.jpg "Briefs: Cipla and IOL Chemicals and Pharmaceuticals")
Briefs: Cipla and IOL Chemicals and Pharmaceuticals
By IPP Bureau - January 21, 2025
Mesalazine is used to treat inflammatory bowel disease
